FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Bacteriophage topics
Bacteriophage
Amplification
Nucleic Acid
Eukaryotic
Prokaryotic
Antibodies
Antibiotic
Bacterial Infection
Adverse Effect
Staphylococcus Aureus
Pseudomonas Aeruginosa
Biotechnology
Staphylococcus
Recombinant
Biomolecule

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Bacteriophage patents



      
           
This page is updated frequently with new Bacteriophage-related patents. Subscribe to the Bacteriophage RSS feed to automatically get the update: related Bacteriophage RSS feeds.

Subscribe to updates on this page: Bacteriophage RSS RSS

Date/App# patent app List of recent Bacteriophage-related patents
04/17/14
20140106982
 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages patent thumbnailPlasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (vlps), especially including ms2 or pp7 vlps. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single rna.
04/17/14
20140105924
 Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods patent thumbnailImmunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of human papillomavirus (hpv) infections and related disorders, including cervical cancer and persistent infections associated with hpv. Related compositions (e.g.
04/17/14
20140105866
 Bacteriophages useful for the prophylaxis and therapy of vibrio anguillarum patent thumbnailBacteriophages useful for the prophylaxis and therapy of vibrio anguillarum
An isolated strain of bacteriophage, specific against bacteria belonging to the vibrio genre, particularly the anguillarum species, deposited on 3 oct. 2012 at the polish collection of microorganisms (pcm) of the ludwik hirszfeld institute of immunology and experimental therapy of the polish academy of sciences, with access number f/00072, characterized in that said strain is efficient in the prophylaxis, control and/or treatment of the infection caused by vibrio anguillarum in all types of species of fish, mollusks and crustaceans that are important for aquaculture susceptible to this bacteria, genome size 48.6 kb, it is not sensitive to chloroform and its storage temperature is −80° c..
04/17/14
20140102975
 Process for reducing bio-corrosion in water systems patent thumbnailProcess for reducing bio-corrosion in water systems
Bacterial contamination of industrial water systems lead to bacterial induced corrosion. This invention provides a method for control of corrosion of industrial water systems caused by bacteria by the destruction of targeted problematic bacteria with naturally occurring, non-engineered bacteriophage virulent for targeted bacteria.
04/10/14
20140099673
 Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium patent thumbnailProcess for the production of hyaluronic acid in escherichia coli or bacillus megaterium
The present invention relates to a method of producing hyaluronic acid (ha) in escherichia coli and bacillus megaterium through episomal plasmid vectors wherein the gene is under the control of strong promoter t7, preferably under the control of strong promoter t7 of bacteriophage t7, and a system for the selection of stable bacterial strains producing high levels of hyaluronic acid.. .
03/27/14
20140086880
 Method for treating neurodegenerative tauopathy patent thumbnailMethod for treating neurodegenerative tauopathy
The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a β-amyloid antigen or an antibody to β-amyloid, or (iii) a tau protein antigen or an antibody to tau protein..
03/20/14
20140079808
 Inhibition of biofilms in plants with imidazole derivatives patent thumbnailInhibition of biofilms in plants with imidazole derivatives
Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein.
03/20/14
20140079671
 Antibacterial phage, phage peptides and methods of use thereof patent thumbnailAntibacterial phage, phage peptides and methods of use thereof
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage f387/08, f391/08, f394/08, f488/08, f510/08, f44/10, and f125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies..
03/13/14
20140072549
 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria patent thumbnailStreptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including streptococcus and staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing streptococcus suis derived bacteriophage lysins, particularly plyss2 and/or plyss1 lytic enzymes and variants thereof, including truncations thereof.
03/06/14
20140065127
 Staphylococcus haemolyticus prophage phish2 endolysin is lytic for staphylococcus aureus patent thumbnailStaphylococcus haemolyticus prophage phish2 endolysin is lytic for staphylococcus aureus
Methicillin-resistant (mrsa) and multi-drug resistant strains of staphylococcus aureus are becoming increasingly prevalent in both human and veterinary clinics. S.
03/06/14
20140061123
Prevention and remediation of petroleum reservoir souring and corrosion by treatment with virulent bacteriophage
There is provided a safe, natural, environmentally sound means of controlling bacterial contamination, corrosion, and souring of oil and gas wells and reservoirs that result from bacteria-contaminated water in a well. In one aspect it is a process for remediation of souring of petroleum reservoirs and coalbeds by adding to the water used in flooding and “fracing” operations an effective amount of virulent (non-lysogenic) bacteriophages (phages) specific for problematic target bacteria.
02/06/14
20140037587
Beneficial effects of bacteriophage treatments
The invention relates to use of one or more bacteriophages in vivo in a human or animal in order to induce sensitivity to chemical antibiotics in bacterial cells, where such susceptibility is heritable, independent of continuing bacteriophage metabolism within those cells, and does not relate to the destruction of a biofilm to induce such sensitivity.. .
01/30/14
20140030699
Electrically conductive polymer electrodes with incorporated viruses
Grafting m13 bacteriophage into an array of poly(3,4-ethylenedioxythiophene) (pedot) nanowires generated hybrids of conducting polymers and replicable genetic packages (rgps) such as viruses. The incorporation of rgps into the polymeric backbone of pedot occurs during electropolymerization via lithographically patterned nanowire electrodeposition (lpne).
01/30/14
20140030697
Sortase-mediated modification of viral surface proteins
The present invention, in some aspects, provides methods, reagents, and kits for the functionalization of proteins on the surface of viral particles, for example, of bacteriophages, using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a detectable label, a binding agent, a click-chemistry handle, or a small molecule to a surface protein of a viral particle.
01/30/14
20140030382
Bacteriophage treated food products
Food treated with bacteriophage, as to reduce or prevent the growth of undesirable bacteria. The food may be coated with bacteriophage and rubbed to distribute the phage on the food surface.
01/30/14
20140030306
Methods and compositions for remediating microbial induced corrosion and environmental damage, and for improving wastewater treatment processes
A method for remediating bacterially-induced corrosion, environmental damage, and/or process inefficiencies in an industrial process includes identifying an industrial process where target bacteria adversely affect corrosion, environmental impact, and/or process efficiencies. The process also includes identifying the strains of the target bacteria, obtaining a bacteriophage virulent against one or more of the strains of the target bacteria, and exposing the target bacteria to the bacteriophage.
01/16/14
20140017205
Bacteriophage and antibacterial composition comprising the same
Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more salmonella bacteria selected from the group consisting of salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, and salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by salmonella enteritidis, salmonella typhimurium, salmonella gallinarum or salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, and pullorum disease or for controlling the salmonella bacteria.
01/16/14
20140014132
Inactivation of bacteriophages in a liquid
The present invention relates to inactivation of bacteriophages in a liquid, such as bacterial growth medium, milk and whey.. .
12/19/13
20130337435
M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications
Reactive and modified m13 bacteriophages, and methods of making and using the same, are generally provided. The reactive m13 bacteriophage can include a alkyne functional group covalently attached to the m13 bacteriophage.
12/19/13
20130336932
Novel salmonella bacteriophage and uses thereof
The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of salmonella species in various settings (e.g., food safety, sanitation, probiotics).. .
12/05/13
20130323209
Novel bacteriophage and its use for preventing proliferation of pathogenic bacteria
The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a composition for treating ballast water, an antibiotic, an antiseptic, a feed additive and the like.. .
11/28/13
20130315874
Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein.
11/28/13
20130315869
Bacteriophages for reducing toxicity of bacteria
Uses thereof and kits comprising same are also disclosed.. .
11/14/13
20130303393
Immunoglobulin libraries
Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain.
11/14/13
20130302371
Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of respiratory syncytial virus (rsv) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g.
11/14/13
20130302306
Bacteriophage lysin and antibiotic combinations against gram positive bacteria
The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly staphylococcal bacteria, with combinations of lysin, particularly streptococcal lysin, particularly the lysin plyss2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).. .
11/07/13
20130295647
Method of producing bacteriophage preparations comprising purification using affinity chromatography
The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography.
11/07/13
20130295554
Methods and compositions for the detection of target molecules
The present disclosure provides methods and compositions for the detection of target molecules, comprising modified bacteriophages engineered to express a luciferase.. .
10/24/13
20130281317
Constructs and methods to identify antibodies that target glycans
Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans.. .
10/17/13
20130273635
Bacteriophage killing pseudomonas aeruginosa and staphylococcus aureus
According to the present invention, the bacteriophage pa1Φ can be used to kill said bacteria and reduce the same effectively. Also, it can be used to remove biofilms generated by said bacteria.
09/26/13
20130252231
Biologic machines for the detection of biomolecules
Disclosed are methods, devices and systems for the isolation and detection of biomolecules from a sample. The embodiments, detection of such biomolecules provides for detection of microorganisms.
09/12/13
20130237486
Collagen
The present invention relates to a trimeric fusion protein comprising three polypeptide chains, wherein each polypeptide chain comprises a eukaryotic collagen or collagen-like domain and a prokaryotic or viral trimerisation domain (pvtd). Also provided is a fusion polypeptide comprising a eukaryotic collagen or collagen-like domain and a pvtd.
08/22/13
20130216997
Methods and systems for detection of microorganisms
Disclosed are methods and systems for the isolation and detection of microbes from a sample. The use of binding agents for isolation of a microbe of interest from a sample are described.
08/22/13
20130216996
Electrically conductive polymer nanowires with incorporated viruses
Grafting m13 bacteriophage into an array of poly(3,4-ethylenedioxythiophene) (pedot) nanowires generated hybrids of conducting polymers and replicable genetic packages (rgps) such as viruses. The incorporation of rgps into the polymeric backbone of pedot occurs during electropolymerization via lithographically patterned nanowire electrodeposition (lpne).
08/15/13
20130209408
Bacteriophage-containing therapeutic agents
The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of p.
08/08/13
20130202643
Avirulent salmonella gallinarum variants and pharmaceutical composition using the same
The present invention relates to avirulent salmonella gallinarum variants by inactivating virulence gene clusters of salmonella gallinarum (sg), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.. .
08/01/13
20130196416
Protein and nucleic acid delivery vehicles, components and mechanisms thereof
Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging.
07/25/13
20130189757
Affinity purification of rna under native conditions based on the lambda boxb/n peptide interaction
Reagents, methods, constructs and kits are described for immobilizing or purifying a target rna of interest, based on the interaction of boxb rna with a bacteriophage n peptide, which in turn is linked to an immobilizing moiety capable of binding to a solid support.. .
07/18/13
20130184183
Recombinant bacteriophage and methods for their use
Recombinant p4 bacteriophage containing modified tail fibers having a base plate attachment region (bpar) from a p2 bacteriophage gene h product and a heterologous receptor binding domain (rbd) are disclosed. Methods for the use of the recombinant p4 bacteriophage, such as to detect the presence of a target bacterium in a sample, are also described..
07/18/13
20130183689
Method for detecting and removing endotoxin
The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially ca2+ or mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins..
07/11/13
20130178390
System comprising bacteriophages and particles that contain active substances
The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces.
07/11/13
20130177533
Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.. .
07/04/13
20130172187
Use of aryl carbamates in agriculture and other plant-related areas
Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an aryl carbamate as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein.
06/27/13
20130164374
Reduction in bacterial colonization by administering bacteriophage compositions
The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log.
06/13/13
20130149759
Application of bacteriophages for the control of unwanted bacteria in biofuel production mediated by bacterial reactive agents
A method of reducing process interruptions in biofuel production systems mediated by bacterial reactive agents by reducing the amount of unwanted bacteria without reduction of wanted or useful bacteria. The method comprises applying a phage panel(s) containing phage virulent for unwanted bacteria that does not contain phage phages virulent wanted bacteria.
06/13/13
20130149753
Application of bacteriophages for the control of unwanted bacteria in biofuel production mediated by non-bacterial reactive agents
A method of reducing process interruptions in biofuel production systems by reducing the amount of unwanted bacteria in the biofuel production system in which the reduction is effected by the use of an effective amount of one or more types of bacteriophages virulent for at least some strains of the unwanted bacteria.. .
06/06/13
20130143274
Methods for nucleic acid manipulation
A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor.
06/06/13
20130143273
Methods for nucleic acid manipulation
A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor.
05/30/13
20130137146
Methods for nucleic acid manipulation
A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor.
05/30/13
20130137145
Methods for nucleic acid manipulation
A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor.
05/23/13
20130133092
Sequence-specific dna recombination in eukaryotic cells
The present invention relates to a method of sequence specific recombination of dna in eukaryotic cells utilizing att sequences from the bacteriophage lambda. A particular embodiment of the invention relates to a method further comprising performing the sequence specific recombination of dna with an int and a xis factor.
05/23/13
20130130313
Method of synthesizing a suppressor trna, dna construct and use thereof for producing a non-natural amino acid-incorporated protein
There are provided a dna construct comprising a suppressor trna gene of a non-eukaryote containing no internal promoter functioning in a eukaryotic cell, and a eukaryotic or bacteriophage promoter linked at the 5′ end of the trna gene, a method for synthesizing a suppressor trna by using the dna construct, and a process for producing protein incorporating a non-natural amino acid by using the same.. .
05/23/13
20130130255
Optical mapping of genomic dna
A method for single-molecule optical dna profiling using an exceptionally dense, yet sequence-specific coverage of dna with a fluorescent probe, using a dna methyltransferase enzyme to direct the dna labeling, followed by molecular combing of the dna onto a polymer-coated surface and subsequent sub-diffraction limit localization of the fluorophores. The result is a ‘dna fluorocode’; a simple description of the dna sequence, with a maximum achievable resolution of less than 20 bases, which can be read and analyzed like a barcode.
05/23/13
20130129697
Enhanced staphylolytic activity of the staphylococcus aureus bacteriophage vb_saus-philpla88 virion-associated peptidoglycan hydrolase hydh5: fusions, deletions and synergy with lysh5
Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse gram positive bacteria on contact. Full-length hydh5, a virion-associated peptidoglycan hydrolase from the staphylococcus aureus bacteriophage vb_saus-phi-ipla88, and two truncated derivatives, containing only the chap domain, exhibited high lytic activity against live s.
05/16/13
20130122033
Fimh vaccine against urinary tract infections (uti)
A engineered bacteriophage is herein described, displaying at its surface multiple copies of a polypeptide, which comprises a domain of the bacterial adhesion protein fimh fused with the coat protein pviii. The domain is preferably the region 45-159aa of the mature protein fimh.
05/16/13
20130121967
Bacteriophages for use against bacterial infections
The present invention relates to a composition comprising obligate lytic bacteriophages generated by a method comprising subjecting normally in vivo lysogenic, pseudolysogenic or temperate bacteriophages to genetic modifications in vitro, which alters the biological activity of one or more of the individual gene products for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages, thereby converting them to obligate lytic bacteriophages, wherein the genetic modification includes modification of a single gene in the operon containing a gene resulting in a gene product for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages.. .
05/09/13
20130115189
Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
The present invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and/or prophylaxis of type ii diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a virus-like particle of an rna bacteriophage and an antigen, wherein said antigen comprises an interleukin-1 beta (il-1β) mutein.
04/04/13
20130084337
Pure filamentous bacteriophage and methods of producing same
The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.. .
02/14/13
20130040355
Particle binding
A method of binding bacteriophage to particles. The method comprising the steps of exposing the particles to an electrical discharge and then mixing the activated particles with the bacteriophage.
01/31/13
20130029351
A25 bacteriophage lysin
The invention relates to the identification, sequencing, and isolation of an a25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria..
01/24/13
20130022579
Bacteriophage and antibacterial composition comprising the same
The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against salmonella typhimurium, salmonella gallinarum, or salmonella pullorum, a composition for the prevention or treatment of infectious diseases including salmonellosis and salmonella food poisoning caused by salmonella typhimurium, fowl typhoid caused by salmonella gallinarum, and pullorum disease caused by salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient. The present invention also provides important insights into prevention and control strategies against salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of salmonella infection in poultry..
01/24/13
20130022574
Avirulent salmonella gallinarum variants and pharmaceutical composition using the same
The present invention relates to avirulent salmonella gallinarum variants by inactivating virulence gene clusters of salmonella gallinarum (sg), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.. .
01/17/13
20130017578
Muteins of the bacteriophage lambda integrases
The present invention refers to muteins of the bacteriophage lambda integrases and to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of the lambda integrases. The invention further refers to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the lambda integrases.
01/17/13
20130017210
Display of antibody fragments on virus-like particles of rna bacteriophages
The invention enables the display of antibody single-chain variable fragments (scfv's on virus-like particles (vlps) of bacteriophages such as ms2. The vlps encapsidate mrna encoding the coat protein from which it assembles, enabling the recovery by reverse transcription and pgr of affinity-selected sequences from scfv libraries.
01/10/13
20130011431
Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
The present invention relates to compositions comprising a construct comprising the aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the alzheimer's type. In one embodiment, the construct containing the aβ1-6 peptide consists of a virus-like particle (vlp) of the rna bacteriophage qβ chemically coupled to said aβ1-6 peptide..
01/10/13
20130011369
Method for prevention and treatment of salmonella infection
The present invention relates to a composition comprising bacteriophage sp-1, the bacteriophage capable of destroying salmonella once being infected in salmonella, as an active ingredient, and a method for prevention and treatment of salmonella infection using the same. Bacteriophage sp-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to salmonella and has the genome represented by seq.
01/03/13
20130004476
Chimeric polypeptides and their use in bacterial decolonization
The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (cbd) and a second portion, which comprises an enzymatic active domain (ead) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors.


Popular terms: [SEARCH]

Bacteriophage topics: Bacteriophage, Amplification, Nucleic Acid, Eukaryotic, Prokaryotic, Antibodies, Antibiotic, Bacterial Infection, Adverse Effect, Staphylococcus Aureus, Pseudomonas Aeruginosa, Biotechnology, Staphylococcus, Recombinant, Biomolecule

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Bacteriophage for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bacteriophage with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4005

3336

0 - 1 - 68